SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MEDSIR Presents Final TUXEDO-3 Study Results

The study evaluates patritumab deruxtecan for active brain metastases and leptomeningeal disease. The supplied body is truncated.

Related stories